Patient Guide: Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 18 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06532656
Status: 🟢 Enrolling Now
Condition: HIV-1-infection
Phase: PHASE2, PHASE3

Where You Can Participate

This study is available at 18 locations across the country.

Top locations include:
  • • Washington D.C., District of Columbia
  • • Tampa, Florida
  • • Atlanta, Georgia
  • • And 15 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 - Join Clinical Trial NCTNCT06532656

How to Join This Clinical Trial - NCTNCT06532656

Learn how to participate in this PHASE2, PHASE3 trial studying an investigational therapy for HIV-1-infection. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with HIV-1-infection. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
HIV-1-infection
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2, PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06532656 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 18 locations. Find a study site near you:

Clinical Research Site

Washington D.C., District of Columbia 20010 - United States

Status: RECRUITING

Clinical Research Site

Tampa, Florida 33612 - United States

Status: RECRUITING

Clinical Research Site

Atlanta, Georgia 30308 - United States

Status: RECRUITING

Clinical Research Site

Chicago, Illinois 60614 - United States

Status: RECRUITING

Clinical Research Site

Buenos Aires, C1141ACG, - Argentina

Status: RECRUITING

Clinical Research Site

Milan, 20157 - Italy

Status: RECRUITING

Clinical Research Site

Roma, 00165 - Italy

Status: RECRUITING

Clinical Research Site

Cape Town, 7505 - South Africa

Status: ACTIVE_NOT_RECRUITING

Clinical Research Site

Cape Town, 7646 - South Africa

Status: RECRUITING

Clinical Research Site

Durban, 3629 - South Africa

Status: RECRUITING

And 8 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2, PHASE3 clinical trial for HIV-1-infection:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships